2 results
Approved WMORecruiting
To evaluate recurrent dysphagia, due to tissue overgrowth or migration, of the SX-Ella stent Esophageal HV in patients with dysphagia from inoperable carcinoma of the distal esophagus or cardia.
Approved WMOCompleted
Primary objectives: 1) Phase Ib: To estimate the MTD or RP2D of INC280 in combination with gefitinib in NSCLC patients who have c-MET dysregulation. 2) Phase II: To estimate overall clinical activity of INC280 in combination with gefitinib in NSCLC…